Brinzolamide – 5 mg

Brand:
Cayman
CAS:
138890-62-7
Storage:
-20
UN-No:
Non-Hazardous - /

Brinzolamide is a potent inhibitor of carbonic anhydrase II (CAII) and CAIV (IC50s = 3.19 and 45.3 nM, respectively).{53202} It is selective for CAII and CAIV over CAI (IC50 = ~1,365 nM). Brinzolamide (30 mg/kg) reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice. Topical administration of brinzolamide (0.25, 0.5, and 1 mg/eye) reduces intraocular pressure (IOP) in a rabbit model of spontaneous ocular hypertension. It also reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension. Formulations containing brinzolamide have been used in the treatment of glaucoma and ocular hypertension.  

 

Available on backorder

SKU: 11660 - 5 mg Category:

Description

A potent carbonic anhydrase inhibitor (IC50s = 3.19 and 45.3 nM for CAII and CAIV, respectively); selective for CAII and CAIV over CAI (IC50 = ~1,365 nM); reduces intestinal charcoal meal progression by 44% and prolongs pentobarbital sodium-induced sleep time by 35% in mice at 30 mg/kg; topical administration reduces intraocular pressure in a rabbit model of spontaneous ocular hypertension at 0.25, 0.5, and 1 mg/eye; reduces IOP in a cynomolgus monkey model of argon laser trabeculoplasty-induced ocular hypertension


Formal name: 4R-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-1,1-dioxide-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

Synonyms:  AL 4862

Molecular weight: 383.5

CAS: 138890-62-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Carbonic Anhydrase||Research Area|Neuroscience|Ophthalmology